Multiple Low-Dose Infusions of Human Umbilical Cord Blood Cells Improve Cognitive Impairments and Reduce Amyloid-β-Associated Neuropathology in Alzheimer Mice

Darlington, Donna; Deng, Juan; Giunta, Brian; Hou, Huayan; Sanberg, Cyndy D.; Kuzmin-Nichols, Nicole; Zhou, Huadong; Mori, Tomohisa; Ehrhart, Jared; Sanberg, Paul R.; Tan, Jun

doi:10.1089/scd.2012.0345

Cited by 42 publications

(40 citation statements)

References 67 publications

(120 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite these obstacles, numerous studies have demonstrated improvements in learning and memory by transplanting neural stem cells to the brains of rodents modeling AD [139][140][141][142][143][144][145][146][147][148] . In addition, transplantation of adipose-derived stem cells to mouse models of AD have shown restoration of memory deficits [149][150][151] and human umbilical cord-derived MSCs that have been differentiated to neuron-like cells also improve cognitive function in AD mouse models [152,153] . The various stem cell types used in transplantation studies in rodent models of AD are summarized in [154,155] .…”

Section: Stem Cell Transplantation For Neurological Disordersmentioning

confidence: 99%

Applications of the Keap1–Nrf2 system for gene and cell therapy

Pomeshchik

Leinonen

Malm

et al. 2015

Free Radical Biology and Medicine

View full text Add to dashboard Cite

Section: Stem Cell Transplantation For Neurological Disordersmentioning

confidence: 99%

Applications of the Keap1–Nrf2 system for gene and cell therapy

Pomeshchik

Leinonen

Malm

et al. 2015

Free Radical Biology and Medicine

View full text Add to dashboard Cite

“…hUCB-MSCs demonstrated considerable extension of life and ameliorated AD in transgenic mice [56] . Additionally, this type of cell also correlates with decreases in cognitive impairment, Aβ levels/ β-amyloid plaques, amyloidogenic APP processing, and reactive microgliosis after treatment [57,58] with a paracrine mechanism [59] .…”

Section: (4) Umbilical Cord Blood Cells and Related Cellsmentioning

confidence: 93%

Cell-based therapy in Alzheimer's disease: Current knowledge and perspective

Qiao

Huang²,

Chen

2016

Transl. Neurosci. Clin.

View full text Add to dashboard Cite

KEYWORDSAlzheimer's disease; cell therapy; stem cells; neurogenesis Alzheimer's disease (AD) is the most prevalent type of dementia, and its neuropathology is characterized by the deposition of insoluble β-amyloid (Aβ) peptides, intracellular neurofibrillary tangles, amyloid angiopathy, age-related brain atrophy, synaptic pathology, white matter rarefaction, granulovacuolar degeneration, neuron loss, and neuroinflammation. Although much is known about the neurobiology of AD, very few conventional therapies are available to arrest or slow the disease. There is an urgent need for novel therapeutic approaches for AD. AD subjects have significantly fewer viable precursor cells in the hippocampus compared with age-matched healthy control subjects. However, the viable precursor cells that remain in AD and age-matched healthy control brain specimens can be induced to differentiate. To facilitate or mimic the natural compensatory effect in AD, cell therapy, including endogenous and exogenous stem cells, has been considered in AD. In this review, we focus on the history and development of cell therapy in AD, and consider the role of cell therapy as a potential treatment for AD.Citation Qiao LY, Huang HY, Chen L. Cell-based therapy in Alzheimer's disease: Current knowledge and perspective. Transl. Neurosci. Clin. 2016, 2(1): 50-58.

show abstract

“…показали, [61]. Неврологическое улучше-ние при трансплантации МНК пуповинной кро-ви продемонстрировано также в моделях трав-мы головного и спинного мозга [7,44], детского церебрального паралича (ДЦП) [53], болезни Альцгеймера [14] и бокового амиотрофического склероза [19]. Клиническая апробация клеток пуповинной крови показала безопасность и эффективность в лечении гипоксически-ишемической энцефа-лопатии новорожденных [13], ДЦП [31,56] и ау-тизма [47].…”

Section: Chernykh Er Et Al черных ер и др Medical Immunology (Runclassified

The Role of Macrophages in Damage Recovery of Central Nervous System: New Options for Treatment of Neurological Disorders

Рэмовна¹,

Shevela²,

Ostanin³

2017

Med. immunol.

View full text Add to dashboard Cite

Адрес для переписки:Черных Елена Рэмовна ФГБНУ «Научно-исследовательский институт фундаментальной и клинической иммунологии» 630099, Россия, г. Новосибирск, ул. Ядринцевская, 14. Тел.: 8 (383) 236-03-29. Факс: 8 (383) 222-70-28. Е-mail: ct_lab@mail.ru Address for correspondence:Chernykh Elena R. Research Institute of Fundamental and Clinical Immunology 630099, Russian Federation, Novosibirsk, » // Медицинская иммунология, 2017. Т. 19, № 1. С. 7-18. doi: 10.15789/1563-0625-2017-1-7-18 © Черных Е.Р. и соавт., 2017 /Meditsinskaya Immunologiya, 2017, Vol. 19, no. 1, pp. 7-18. doi: 10.15789/1563-0625-2017 Резюме. Смена существующих парадигм относительно регенеративного потенциала центральной нервной системы (ЦНС) и роли иммунных клеток в процессах восстановления поврежденной нерв-ной ткани открывают новые перспективы лечения неврологических расстройств на основе иммуно-терапевтических подходов. Настоящий обзор посвящен анализу роли макрофагов в восстановлении повреждений в ЦНС и включает данные о функциональной гетерогенности клеток микроглии и ма-крофагов моноцитарного происхождения, путях рекрутирования моноцитов в ЦНС, взаимоотноше-нии клеток микроглии и рекрутируемых макрофагов и балансе М1/М2-клеток при нейропатологии. Кроме того, в обзоре приводится экспериментальное обоснование участия макрофагов в восстанов-лении повреждений ЦНС и рассматриваются механизмы регенеративной активности макрофагов. Приведенные данные позволяют рассматривать макрофаги в качестве новой мишени терапевти-ческих воздействий для подавления нейровоспалительной реакции и усиления репаративных про-цессов. Первые шаги в этой области свидетельствуют о перспективности применения моноцитов/ макрофагов или технологий М1→М2 переключения в лечении неврологических расстройств и обо-сновывают необходимость дальнейших исследований в данном направлении. Ключевые слова: ЦНС, макрофаги, микроглия, макрофаги моноцитарного происхождения, функциональные фенотипы, нейропротекция, нейрорегенерация, ангиогенез, ДЦП, инсульт, регенеративная иммунотерапия THE ROLE OF MACROPHAGES IN DAMAGE RECOVERY OF CENTRAL NERVOUS SYSTEM: NEW OPTIONS FOR TREATMENT OF NEUROLOGICAL DISORDERSChernykh E.R., Shevela E.Ya., Ostanin A.A. Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russian FederationAbstract. Evolution of existing paradigms on regenerative capacity of the central nervous system (CNS) and eventual role of immune cells in restoration of damaged nervous tissue offers new prospectives in treatment 8 Chernykh E. R. et al. Черных Е.Р. и др. Medical Immunology (Russia)/Meditsinskaya Immunologiya Медицинская Иммунология of neurological disorders based on immunotherapeutic approaches. Present review article addresses a role of macrophages in restoration of damaged CNS and provides data on functional heterogeneity of resident tissue macrophages (microglia), and monocyte-derived macrophages. We discuss possible ways of monocyte recruitment to CNS, relationships between microglia and recruited macrophages, as well as M1/M2 ...

show abstract

Multiple Low-Dose Infusions of Human Umbilical Cord Blood Cells Improve Cognitive Impairments and Reduce Amyloid-β-Associated Neuropathology in Alzheimer Mice

Cited by 42 publications

References 67 publications

Applications of the Keap1–Nrf2 system for gene and cell therapy

Applications of the Keap1–Nrf2 system for gene and cell therapy

Cell-based therapy in Alzheimer's disease: Current knowledge and perspective

The Role of Macrophages in Damage Recovery of Central Nervous System: New Options for Treatment of Neurological Disorders

Contact Info

Product

Resources

About